Xeris Biopharma Holdings Inc (XERS)

[crudeoil24]

On June 30, 2020, Xeris Pharmaceuticals, Inc. (the “Company”) completed its previously announced underwritten public offering (the “Notes Offering”) of $75.0 million aggregate principal amount of the Company’s 5.00% Convertible Senior Notes due 2025 (the “Notes”). As previously announced, the Company granted the underwriters of the Notes Offering a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of Notes, solely to cover over-allotments. As of the date of this Current Report on Form 8-K, the underwriters of the Notes Offering have not exercised their option to purchase additional Notes.